Why is bioAffinity Technologies, Inc. ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Negative results in Sep 25
- OPERATING CASH FLOW(Y) Lowest at USD -8.45 MM
- NET SALES(Q) At USD 1.45 MM has Fallen at -38.48%
- NET PROFIT(HY) At USD -5.3 MM has Grown at -28.96%
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -54.20%, its profits have fallen by -29.4%
4
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 13.68% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -54.20% returns
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is bioAffinity Technologies, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
bioAffinity Technologies, Inc.
-54.08%
0.03
2881.03%
S&P 500
13.68%
0.71
19.28%
Quality key factors
Factor
Value
Sales Growth (5y)
67.01%
EBIT Growth (5y)
-224.69%
EBIT to Interest (avg)
-5.67
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.17
Sales to Capital Employed (avg)
0.89
Tax Ratio
0.17%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.02%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.97
EV to EBIT
-0.13
EV to EBITDA
-0.14
EV to Capital Employed
0.81
EV to Sales
0.20
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-620.56%
ROE (Latest)
-122.77%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Bullish
Bullish
Technical Movement
5What is working for the Company
NET PROFIT(HY)
Higher at USD -5.3 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -78.5 %
EPS(Q)
Highest at USD -4.74
-19What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -8.45 MM
NET SALES(Q)
At USD 1.45 MM has Fallen at -38.48%
NET PROFIT(HY)
At USD -5.3 MM has Grown at -28.96%
RAW MATERIAL COST(Y)
Grown by 16.91% (YoY
Here's what is working for bioAffinity Technologies, Inc.
Net Profit
Higher at USD -5.3 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
EPS
Highest at USD -4.74
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Lowest at -78.5 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for bioAffinity Technologies, Inc.
Net Sales
At USD 1.45 MM has Fallen at -38.48%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Operating Cash Flow
Lowest at USD -8.45 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Net Profit
At USD -5.3 MM has Grown at -28.96%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Raw Material Cost
Grown by 16.91% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales






